Skip to main content
OpenTrials
Completed

NCT Number: NCT05842434

Pilot Study of the Felix System in Patients With Essential Tremor and Parkinson's Tremor

A prospective, open-label, multi-center pilot study designed to evaluate the safety and effectiveness of the Felix system in the relief of upper limb tremors in adults with essential tremor and Parkinson's disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Essential Tremor Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years of age.
  • Willing to provide written, informed consent to participate in the study.
  • For subjects with essential tremor (ET):
  • A clinical diagnosis of ET.
  • For either upper limb, a tremor severity score of 2 or higher as measured by one of the TETRAS items and a total score of 6 or higher across all TETRAS tasks.
  • For subjects with Parkinson's disease (PD):
  • A clinical diagnosis of PD (MDS-PD criteria).
  • A tremor score of 2 or higher on MDS-UPDRS question 3.15 (postural tremor) or 3.16 (kinetic tremor), OR
  • A rest tremor score of 2 or higher on MDS-UPDRS question 3.17 (rest tremor amplitude) in one upper extremity and a score of 2 or higher on MDS-UPDRS question 3.18 (constancy of tremor).
  • Stable dosage of any medication, if applicable, for 30 days prior to study entry.
  • Familiar with operating a touch-screen smartphone and connecting to Wi-Fi internet at home.
  • If necessary, have a dedicated caregiver to help with study required activities, such as putting on the study device, etc.
  • Willing to comply with study protocol requirements including:
  • Remaining on a stable dosage of current medications, if applicable, during the course of the study.
  • Remaining on stable caffeine consumption, if applicable, during the course of t the study.
  • No alcohol consumption on the day before a study visit.

Exclusion criteria

  • Prior limb amputation or any known symptomatic peripheral neuropathy condition of the involved upper extremity.
  • Any current drug or alcohol abuse.
  • Current unstable epileptic conditions with a seizure within 6 months of study entry.
  • Pregnant or nursing subjects and those who plan pregnancy during the course of the study.
  • Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at the stimulation site.
  • Known allergy to adhesives.
  • History of Alzheimer's disease or dementia (Montreal Cognitive Assessment (MoCA)≤19).
  • Botulinum Toxin injection for hand tremor within 4 months prior to study enrollment.
  • Subject is currently participating or has participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the Sponsor.
  • Subject is unable to communicate with the investigator and staff.
  • Any health condition that in the investigator's opinion should preclude participation in this study.

Treatment and study plan

Felix NeuroAI Wristband

Device

Felix is a wrist-worn, noninvasive, transcutaneous neurostimulation system intended for daily use to suppress hand tremors. An artificial intelligence (AI) algorithm will automatically adjust the stimulation based on each patient's tremor throughout the day.

Primary outcomes

  1. Tremor Research Group Essential Tremor Rating Assessment (TETRAS) Performance Subscale

    Time frame: Baseline to 7 days

    A subset of 6 performance tasks will be rated by a physician for each upper limb separately. Each task will be rated from 0 to 4, indicating the increasing severity of tremor, the higher the score, the worse the tremor. This endpoint is the total score of all 6 tasks, the minimum score is 0 and the maximum score is 24.

Secondary outcomes

  1. Clinical Global Impression of Improvement (CGI-I)

    Time frame: Baseline to 7 days

    Physician rating of tremor improvement on a 7-point scale, from 1 (very much improved) to 7 (very much worse)

  2. Tremor Research Group Essential Tremor Rating Assessment (TETRAS) Activities of Daily Living (ADL) Subscale

    Time frame: Baseline to 7 days

    Patient rating the impact of tremor on each activity of daily living on a 5-point scale, from 0 (normal) to 4 (severely abnormal). This is a composite endpoint that includes the total score of all 12 items of the TETRAS ADL subscale. The minimum score is 0 and the maximum score is 48.

  3. Patient Global Impression of Improvement (PGI-I)

    Time frame: Baseline to 7 days

    Patient rating of tremor improvement on a 7-point scale, from 1 (very much improved) to 7 (very much worse)

  4. Tremor Research Group Essential Tremor Rating Assessment (TETRAS) Modified Activities of Daily Living (mADL) Subscale

    Time frame: Baselinen to 7 days

    TETRAS mADL score is a composite sum of items 2 to 11 of the TETRAS ADL subscale and items 6 (bilateral) and 7 (dominant hand) of the TETRAS performance subscale (PS). Each item on the TETRAS ADL subsacle and the TETRAS PS subscale is rated from 0 (no tremor) to 4 (severe tremor). TETRAS mADL score is calculated as the sum of all 13 items, the minimum score is 0 and the maximum score is 52.

Sponsors and collaborators

Lead sponsor

Fasikl Inc.

Industry

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
May 6, 2023
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.